Albert Suheil Atallah-Yunes

[Ahmed AlNughmush @AhmedAlNughmush]

Right before the end of the year!

Out now @AjHematology

We characterize the features and outcomes of an uncommonly encountered subtype of MALT lymphoma.

Primary Breast MALT Lymphoma
https://t.co/xkzjFo3lBf

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies #lymsm https://t.co/AigqLXukuZ

[Matthew Rees @MattReesMD]

New @AlbertYunes study: EBV+ polymorphic B-cell LPD (NOS) — first real-world cohort outside the transplant setting.
🧍‍♂️31 pts | Strong responses to rituximab ± immunosuppression reduction.
🧠 CNS cases can remit; rebiopsy crucial at relapse.
🔗 https://t.co/jJZMRcPSZ9

[AmericanJournalofHematology @AjHematology]

In the largest cohort of #ALK+ LBCL to date, poor outcomes persisted despite intensified frontline chemotherapy or frontline ASCT. Integration of biologically informed therapies may have improved survival compared to historical data. #lymphoma
https://t.co/S31KSIrZ5R @AlbertYunes

[Albert Suheil Atallah-Yunes @AlbertYunes]

Excited to share our multi-institutional study on ALK+ Large B-cell lymphoma in @AjHematology :
Outcomes remain poor with intensified chemo and consolidative ASCT. Select durable remissions occurred with biologically targeted therapies & allo-SCT
https://t.co/3LgZWUjDIx

[Alex Rampotas @ARampotas]

Thrilled to share our latest study on secondary myeloid malignancies after CAR-T cell therapy led by Dr Francesca Sillito
@uclh @drclaireroddie @Capt__Kirkwood @Haematologica
https://t.co/LVpBMVrdYG

[Blood Cancer Journal @BloodCancerJnl]

Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection | Blood Cancer Journal ⁦@MayoCancerCare⁩ https://t.co/gcVIH4cHrZ

[Albert Suheil Atallah-Yunes @AlbertYunes]

@DrRaulCordoba @MayoCancerCare Thanks so much Raul! Much appreciated!!

[Albert Suheil Atallah-Yunes @AlbertYunes]

Proteomic determinants of renal organ response in light-chain amyloidosis: Amyloid: Vol 0, No 0 https://t.co/LloJr70j9H @MattReesMD

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology CODOX-M/IVAC-R vs DA-EPOCH-R in double-hit/triplehit #lymphoma patients aged 60 years or under | ⁦@Haematologica⁩ #lymsm https://t.co/8eiRN7lHJt

[AmericanJournalofHematology @AjHematology]

Characteristics & outcomes of incidentally diagnosed large B cell #lymphoma. Patients have lower stage & IPI scores compared to symptomatic patients. Potential insight into what could be seen with multi-cancer early detection tests https://t.co/KfN2cEAhsQ
@AlbertYunes

[Raul Cordoba, MD, PhD @DrRaulCordoba]

Apply for #EHACRTH

@EHA_Hematology “Clinical #Research Training in #Hematology” provides early-researchers with a unique, year-long training and mentoring experience.

Apply by September 24,
15:00 CEST.

https://t.co/bRpnVFnukS

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#CRTH2024 has come to its end. Amazing scholars, high expertise faculty, extraordinary organization. Thanks to @EHA_Hematology for this outstanding #mentoring experience. Proud to be part of it. Looking forward to next year edition. Please, apply!! https://t.co/XCJuHZQlhA

[European Hematology Association @EHA_Hematology]

After a full day of working on projects, our #EHACRTH scholars took part in a teambuilding activity. CRTH is an opportunity to learn more than just clinical trials, but build new connections too (not to mention cooking skills).
Learn more: https://t.co/atHWJO4dSN

#YoungEHA

[European Hematology Association @EHA_Hematology]

#EHA would like to congratulate this year's #EHACRTH scholars on completing the first workshop, offering insights into trial funding, working with the industry, patient safety and reporting, working with statisticians, and more.
Learn more about CRTH: https://t.co/atHWJO4dSN

[Raul Cordoba, MD, PhD @DrRaulCordoba]

@EHA_Hematology #EHACRTH “Clinical #Research Training in #Hematology” Workshop 1 has come to its end. Amazing progress done by scholars. Looking forward to seeing you all in Madrid at #EHA2024. Safe trips back home! #networking #mentoring

[Nico Gagelmann @NicoGagelmann]

🎉Finally out🎉

Real-world results of CAR-T cell therapy for large B-cell lymphoma with CNS involvement ⁦@BloodAdvances⁩ #lymsm https://t.co/QitujtudSh

[Lymphoma Hub @lymphomahub]

CONGRESS #EHA2023 | @gilles_salles @MSKCancerCenter discusses a phase I/II trial of epocoritamab vs axi-cel in R/R DLBCL CAR-T naïve & eligible pts. There was no sig. difference in ORR or CR rates for CAR T-naive vs axi-cel. Results were similar for Ep vs Axi-cel #lymsm #lymphoma

[Toby Eyre @tobyeyre82]

Important future question:
Venetoclax or Pirtobrutinib after a covalent BTKi?
#EHA2023 #CLL #venetoclax #pirtobrutinib

[Fawzi Abu Rous, MD @FawziAbuRous]

Best part about #ASCO23 is connecting with med school friends! #LCSM #OncTwitter @UJ_MED @AlbertYunes @enaddawod